• About us
• Contact

Advertisement

Collaboration › Details

Affimed–Wells Fargo: investor conference, 201809 supply service Affimed presents at Wells Fargo Healthcare Conference in Boston

 

	Period	2018-09-06
	Region	Boston, MA
	Country	United States (USA)
	Partner, 1st	Affimed N.V. (Nasdaq: AFMD)
	Group	Affimed (Group)
	Partner, 2nd	Wells Fargo Securities LLC
	Product	Wells Fargo Healthcare Conference 2016 Boston
	Product 2	TandAb bispecific antibody
	Person	Hoess, Adi (Affimed 201109– CEO before CCO before Jenowis + Jerini 2003– + Carl Zeiss AG + MorphoSys AG)
	Person 2	Gin, Gregory (Affimed 201808 Head of Investor Relations)

Affimed N.V.. (8/30/18). "Press Release: Affimed to Present at the 2018 Wells Fargo Securities Healthcare Conference". Heidelberg.

Affimed N.V. (Nasdaq: AFMD), a clinical stage biopharmaceutical company focused on discovering and developing highly targeted cancer immunotherapies that harness the power of innate and adaptive immunity (NK and T cells), today announced that Dr. Adi Hoess, Affimed’s CEO, will present at the 2018 Wells Fargo Securities Healthcare Conference on Thursday, September 6, 2018 at 8:35 a.m. ET in Boston.

A live webcast of the conference presentation can be accessed through the “Events” section on the “Investors & Media” page of the Affimed website at http://www.affimed.com/events.php. A replay of the presentation will be available from Affimed’s website for 30 days following the conference.


About Affimed N.V.

Affimed (Nasdaq: AFMD) engineers targeted immunotherapies, seeking to cure patients by harnessing the power of innate and adaptive immunity (NK and T cells). We are developing single and combination therapies to treat cancers and other life-threatening diseases. For more information, please visit www.affimed.com.


Affimed Investor Contact:
Gregory Gin, Head of Investor Relations
E-Mail: IR@affimed.com

Affimed Media Contact:
Anca Alexandru, Head of Communications, EU IR
E-Mail: media@affimed.com

Record changed: 2022-11-19

Advertisement

More documents for Affimed (Group)

• [1] Affimed N.V.. (3/6/24). "Press Release: Affimed Announces 1-for-10 Reverse Stock Split". Mannheim....
• [2] Affimed N.V.. (1/3/24). "Press Release: Affimed Announces Sale of Wholly-Owned Subsidiary AbCheck". Mannheim....
• [3] Affimed N.V.. (11/3/22). "Press Release: Affimed and Artiva Biotherapeutics Announce Partnership to Advance Combination Therapy of Innate Cell Engager (ICE) AFM13 and Off-the-Shelf Allogeneic NK Cell Therapy AB-101". Heidelberg & San Diego, CA....
• [4] Affimed N.V.. (11/1/22). "Press Release: Affimed to Present at the 2022 Jefferies London Healthcare Conference". Heidelberg....
• [5] Affimed N.V.. (9/1/22). "Press Release: Affimed to Present at Upcoming Investor Conferences". Heidelberg....
• [6] Affimed N.V.. (4/13/22). "Press Release: Affimed Announces Pricing of Upsized $90 Million Public Offering of Common Shares". Heidelberg....
• [7] Affimed N.V.. (4/12/22). "Press Release: Affimed Announces Proposed Public Offering of Common Shares". Heidelberg....
• [8] Affimed N.V.. (4/10/22). "Press Release: Affimed Presents Updated Clinical Data from Phase 1/2 Study of AFM13 Precomplexed with Cord Blood-Derived NK Cells at AACR Annual Meeting". Heidelberg....
• [9] Affimed N.V.. (4/8/22). "Press Release: Affimed Presents Findings from the Dose-escalation Phase of the First-in-human Study of AFM24 in Patients with EGFR-positive Solid Tumors". Heidelberg....
• [10] Affimed N.V.. (3/31/22). "Press Release: Affimed Reports 2021 Financial Results and Highlights Recent Operational Progress". Heidelberg....

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Please visit also our web portals for the European life sciences and the worldwide mass spectrometry industry at Life-Sciences-Europe.com (European life sciences) and Mass-Spec-Capital.com (worldwide mass spectrometry)

Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)

Advertisement

» top

» Imprint  |  » Data Privacy  |  » Contact  |  The use of this website requires to accept the » Disclaimer!   |  A project of [iito] Business Intelligence © 2002-2024. Made in Germany.